Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatment Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC Event scheduled for Tuesday, December 2nd at 8:00 AM ET Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting...
Chemung Financial Corporation Announces Quarterly Dividend ELMIRA, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Chemung Financial Corporation (Nasdaq: CHMG) announced today that its Board of Directors has approved a quarterly cash dividend of $0.34 per share, payable on January 2, 2026, to common stock shareholders of record as of the close of business on December 19, 2025. Chemung Financial Corporation is a $2.7 billion financial services holding company headquartered in Elmira, New York and operates 30 offices through its principal subsidiary, Chemung Canal Trust Company, a full-service com...
Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025 Company outlines continued progress executing operational transformation and growth strategy across its dental and medical segments ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued ...
Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company’s financial results for the third quarter ended September 30, 2025, as well as the company’s corporate progress and other developments. The conference call will ...
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around...
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination port...
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy volunteer...
Neumora Therapeutics to Participate in Upcoming Conferences in November WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November. Guggenheim 2nd Annual Healthcare Innovation Conference: Members of management will participate in a fireside chat on Monday, November 10, 2025...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.